Impact of Clinical Presentation (Stable Angina Pectoris vs Unstable Angina Pectoris or Non-ST-Elevation Myocardial Infarction vs ST-Elevation Myocardial Infarction) on Long-Term Outcomes in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents.

PubWeight™: 0.79‹?›

🔗 View Article (PMID 26174605)

Published in Am J Cardiol on June 24, 2015

Authors

Gennaro Giustino1, Usman Baber1, Giulio Giuseppe Stefanini2, Melissa Aquino1, Gregg W Stone3, Samantha Sartori1, Philippe Gabriel Steg4, William Wijns5, Pieter C Smits6, Raban V Jeger7, Martin B Leon3, Stephan Windecker8, Patrick W Serruys9, Marie-Claude Morice10, Edoardo Camenzind11, Giora Weisz12, David Kandzari13, George D Dangas1, Ioannis Mastoris1, Clemens Von Birgelen14, Soren Galatius15, Takeshi Kimura16, Ghada Mikhail17, Dipti Itchhaporia18, Laxmi Mehta19, Rebecca Ortega20, Hyo-Soo Kim21, Marco Valgimigli22, Adnan Kastrati23, Alaide Chieffo24, Roxana Mehran25

Author Affiliations

1: The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York City, New York.
2: Humanitas Research Hospital, Rozzano, Milan, Italy.
3: Columbia University Medical Center, New York City, New York.
4: Département Hospitalo Universitaire Fibrose, Inflammation et REmodelage, Assistance Publique-Hôpitaux de Paris, Université Paris Diderot, INSERM U-1148, Paris, France.
5: Cardiovascular Center Aalst, Onze-Lieve-Vrouwziekenhuis Ziekenhuis, Aalst, Belgium.
6: Maasstad Hospital, Rotterdam, The Netherlands.
7: University Hospital Basel, Basel, Switzerland.
8: Bern University Hospital, Bern, Switzerland.
9: ErasmusMC, Rotterdam, The Netherlands.
10: Department of Cardiology and Cardiovascular Surgery, Institut Cardiovasculaire Paris Sud, Paris, France.
11: University of Geneva, Geneva, Switzerland.
12: Columbia University Medical Center, New York City, New York; Shaare Zedek Medical Center, Jerusalem, Israel.
13: Piedmont Heart Institute, Atlanta, Georgia.
14: Thoraxcentrum Twente, Enschede, The Netherlands.
15: Gentofte University Hospital, Hellerup, Denmark.
16: Kyoto University Graduate School of Medicine, Kyoto, Japan.
17: Imperial College Healthcare NHS Trust, London, United Kingdom.
18: Hoag Memorial Hospital Presbyterian, Newport Beach, California.
19: Ohio State University Medical Center, Columbus, Ohio.
20: Society of Cardiovascular Angiography and Interventions, Washington, DC.
21: Seoul National University Main Hospital, Seoul, Korea.
22: University of Ferrara, Ferrara, Italy.
23: Herzzentrum, Munich, Germany.
24: San Raffaele Scientific Institute, Milan, Italy.
25: The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York City, New York. Electronic address: Roxana.Mehran@mountsinai.org.

Articles by these authors

Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction. J Am Coll Cardiol (2015) 4.35

Transapical versus transfemoral aortic valve implantation: a multicenter collaborative study. Ann Thorac Surg (2013) 2.14

Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial. Eur Heart J (2015) 1.71

Transcatheter aortic valve implantation in failed bioprosthetic surgical valves. JAMA (2014) 1.45

Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization: From the WIN-DES Collaborative Patient-Level Pooled Analysis. JACC Cardiovasc Interv (2016) 1.41

Treatment of aortic stenosis with a self-expanding transcatheter valve: the International Multi-centre ADVANCE Study. Eur Heart J (2014) 1.40

Effect of Chronic Kidney Disease in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: A Patient-Level Pooled Analysis of Randomized Controlled Trials. JACC Cardiovasc Interv (2016) 1.39

Mitral Regurgitation in Low-Flow, Low-Gradient Aortic Stenosis Patients Undergoing TAVR: Insights From the TOPAS-TAVI Registry. JACC Cardiovasc Interv (2020) 1.39

Causes of late mortality with dual antiplatelet therapy after coronary stents. Eur Heart J (2015) 1.38

Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial. JAMA (2015) 1.11

Transcatheter aortic valve implantation with the Edwards SAPIEN versus the Medtronic CoreValve Revalving system devices: a multicenter collaborative study: the PRAGMATIC Plus Initiative (Pooled-RotterdAm-Milano-Toulouse In Collaboration). J Am Coll Cardiol (2013) 0.98

The future of transcatheter mitral valve interventions: competitive or complementary role of repair vs. replacement? Eur Heart J (2015) 0.95

Management of ST-elevation myocardial infarction according to European and American guidelines. EuroIntervention (2014) 0.87

Local and general anaesthesia do not influence outcome of transfemoral aortic valve implantation. Int J Cardiol (2014) 0.85

Comparison of Short- and Long-Term Cardiac Mortality in Early Versus Late Stent Thrombosis (from Pooled PROTECT Trials). Am J Cardiol (2015) 0.81

Treatment of drug-eluting stent restenosis: Comparison between drug-eluting balloon versus second-generation drug-eluting stents from a retrospective observational study. Catheter Cardiovasc Interv (2015) 0.81

ACS and STEMI treatment: gender-related issues. EuroIntervention (2012) 0.80

Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients. Eur Heart J (2017) 0.79

One-year outcome of biolimus eluting stent with biodegradable polymer in all comers: the Italian Nobori Stent Prospective Registry. Int J Cardiol (2014) 0.78

Transcatheter Tricuspid Valve Repair With a New Transcatheter Coaptation System for the Treatment of Severe Tricuspid Regurgitation: 1-Year Clinical and Echocardiographic Results. JACC Cardiovasc Interv (2017) 0.78

Barriers to cardiovascular device innovation in Europe. Eur Heart J (2015) 0.76

TCT-213 Efficacy and Safety of Long- Versus Short-Term Dual Antiplatelet Therapy Following Complex Percutaneous Coronary Intervention with Drug-Eluting Stents: A Collaborative Patient-Level Pooled Analysis of Randomized Controlled Trials. J Am Coll Cardiol (2016) 0.75

TCT-66 Effects of dual antiplatelet therapy cessation among patients with diabetes mellitus after PCI with DES. J Am Coll Cardiol (2016) 0.75

Impact of diabetes mellitus on female subjects undergoing transcatheter aortic valve implantation: Insights from the WIN-TAVI international registry. Int J Cardiol (2020) 0.75

TCT-229 Safety and Efficacy of Rotational Atherectomy for the Treatment of Undilatable Underexpanded Stents Implanted in Calcific Lesions. J Am Coll Cardiol (2016) 0.75

TCT-698 Comparison of the fully repositionable and retrievable Lotus Valve and Direct Flow Medical Valve for the treatment of severe aortic stenosis: a high-volume single center experience. J Am Coll Cardiol (2016) 0.75

TCT-361 Targeting Transradial Approach: an Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Am Coll Cardiol (2016) 0.75

TCT-211 Incidence and Impact of Dual Antiplatelet Therapy Cessation on Clinical Outcomes in Patients with Renal Dysfunction: Insights from the PARIS Registry. J Am Coll Cardiol (2016) 0.75

Health Status after Transcatheter vs. Surgical Aortic Valve Replacement in Low-Risk Patients with Aortic Stenosis. J Am Coll Cardiol (2019) 0.75

Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. JAMA Cardiol (2017) 0.75

Bleeding-Related Deaths in Relation to the Duration of Dual-Antiplatelet Therapy After Coronary Stenting. J Am Coll Cardiol (2017) 0.75

Rationale and design of the Hunting for the off-target propertIes of Ticagrelor on Endothelial function and other Circulating biomarkers in Humans (HI-TECH) trial. Am Heart J (2017) 0.75

TCT-718 Predictors of vascular complications in women undergoing contemporary transcatheter aortic valve replacement: A report from the WIN-TAVI registry. J Am Coll Cardiol (2016) 0.75

TCT-219 Influence Of Anemia On Physician-Recommended DAPT Discontinuation After Percutaneous Coronary Intervention. J Am Coll Cardiol (2016) 0.75

Acute Gain in Minimal Lumen Area Following Implantation of Everolimus-Eluting ABSORB Biodegradable Vascular Scaffolds or Xience Metallic Stents: Intravascular Ultrasound Assessment From the ABSORB II Trial. JACC Cardiovasc Interv (2016) 0.75

Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry. Thromb Haemost (2019) 0.75

TCT-351 Coronary sinus reducer implantation for the treatment of chronic refractory angina: a single center experience. J Am Coll Cardiol (2016) 0.75

TCT-420 Incidence of side branch occlusions following bioresorbable scaffold implantation for long left anterior descending artery lesions. J Am Coll Cardiol (2016) 0.75

Impact of Race/Ethnicity on Long Term Outcomes After Percutaneous Coronary Intervention with Drug-Eluting Stents. Am J Cardiol (2022) 0.75

TCT-475 Effect of Stent Diameter in Women Undergoing Percutaneous Coronary Intervention with Early- and New-Generation Drug-Eluting Stents: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. J Am Coll Cardiol (2016) 0.75

TCT-453 Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention with Drug-Eluting Stents: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. J Am Coll Cardiol (2016) 0.75

Short-versus long-term Dual Antiplatelet therapy after drug-eluting stent implantation in women versus men: A sex-specific patient-level pooled-analysis of six randomized trials. Catheter Cardiovasc Interv (2016) 0.75

TCT-206 Tailoring the Intensity of Antiplatelet Pharmacotherapy to Ischemic and Bleeding Risk: A Cost Optimizing Simulation From PARIS. J Am Coll Cardiol (2016) 0.75

TCT-471 Impact of New- versus Early-Generation Drug Eluting Stents in Women according to Age: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. J Am Coll Cardiol (2016) 0.75

Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. JACC Cardiovasc Interv (2016) 0.75

Surgical Revascularization versus Percutaneous Coronary Intervention and Optimal Medical Therapy in Diabetic Patients with Multi-Vessel Coronary Artery Disease. Prog Cardiovasc Dis (2015) 0.75

TCT-204 Optimal duration of dual antiplatelet therapy (DAPT) after second generation drug-eluting stent (DES) implantation in elderly patients: the SECURITY-ELDERLY substudy. J Am Coll Cardiol (2016) 0.75

TCT-400 The importance of implantation technique in ensuring optimal outcomes after bioresorbable scaffold implantation: implications from a real-world cohort. J Am Coll Cardiol (2016) 0.75

TCT-506 Coronary sinus reduction improves myocardial perfusion reserve index assessed by dipyridamole stress cardiac magnetic resonance. J Am Coll Cardiol (2016) 0.75

TCT-418 Procedural and mid-term outcomes of Bioresorbable scaffOlds versus drug-elutiNg stents In chronic Total Occlusions: the BONITO Registry. J Am Coll Cardiol (2016) 0.75

Bicuspid Aortic Valve Morphology and Outcomes After Transcatheter Aortic Valve Replacement. J Am Coll Cardiol (2020) 0.75

TCT-394 Impact of inadequate angiographic results after pre-dilatation on clinical outcomes following drug-coated balloon treatment for in-stent restenosis. J Am Coll Cardiol (2016) 0.75

A challenging case of transcatheter aortic prosthesis dysfunction: Endocarditis or thrombosis? Int J Cardiol (2016) 0.75

TCT-205 Incidence and clinical outcomes associated with DAPT discontinuation in complex PCI patients: From the PARIS registry. J Am Coll Cardiol (2016) 0.75

Efficacy and Safety of Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin, Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization of Patients With Diabetes Mellitus. Am J Cardiol (2019) 0.75